Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference
January 06 2022 - 8:00AM
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of
therapeutics that target galectin proteins, announced today the
Company will be participating in the H.C. Wainwright BioConnect
Conference being held virtually January 10-13, 2022. Mr. Joel
Lewis, President and Chief Executive Officer, and Dr. Pol F.
Boudes, Chief Medical Officer, will be presenting on behalf of the
Company.
A webcast of this presentation will be available on
the “Investor Relations” section under “Events and Presentations”
of the Company’s
website, https://investor.galectintherapeutics.com, at 7:00
a.m. ET on January 10, 2022. A replay will be accessible on
Galectin’s website for 90 days following the event.
About Galectin
TherapeuticsGalectin Therapeutics is dedicated to
developing novel therapies to improve the lives of patients with
chronic liver disease and cancer. Galectin’s lead drug belapectin
is a carbohydrate-based drug that inhibits the galectin-3 protein
which is directly involved in multiple inflammatory, fibrotic, and
malignant diseases, for which it has Fast Track designation by the
U.S. Food and Drug Administration. The lead development program is
in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most
advanced form of NASH-related fibrosis. This is the most common
liver disease and one of the largest drug development opportunities
available today. Additional development programs are in treatment
of combination immunotherapy for advanced melanoma and other
malignancies. Advancement of these additional clinical programs is
largely dependent on finding a suitable partner. Galectin seeks to
leverage extensive scientific and development expertise as well as
established relationships with external sources to achieve
cost-effective and efficient development. Additional information is
available
at www.galectintherapeutics.com.
Company
Contact:
Jack Callicutt, Chief
Financial Officer(678) 620-3186ir@galectintherapeutics.com
Galectin Therapeutics and
its associated logo is a registered trademark of Galectin
Therapeutics Inc. Belapectin is the USAN assigned name for Galectin
Therapeutics’ galectin-3 inhibitor GR-MD-02.
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Jul 2023 to Jul 2024